Literature DB >> 34972751

Combination of GATA3, SOX-10, and PAX8 in a Comprehensive Panel to Diagnose Breast Cancer Metastases.

Kiyong Na1, Ha Young Woo2, Sung-Im DO3, So-Woon Kim4.   

Abstract

BACKGROUND/AIM: It can be difficult to establish the origin of a tumor in metastatic breast cancer (MBC), especially with triple-negative breast cancer (TNBC) or high-grade features. We evaluated the diagnostic utility of GATA3, SOX10, and PAX8 panels in MBC by comparing their expression in each molecular subtype of MBC. PATIENTS AND METHODS: We evaluated 84 MBC and 37 primary TNBC cases using GATA3, SOX10, and PAX8 staining in whole tissue sections.
RESULTS: GATA3 was least sensitive in the detection of metastatic TNBC (metastatic non-TNBC, 0.95; metastatic TNBC, 0.37). SOX10 had the lowest overall sensitivity (0.12) but was elevated in metastatic TNBC, even higher than GATA3 (0.59 vs. 0.37). The combination of GATA3, SOX10, and PAX8 expression showed the highest detection rate (MBC, 0.94; metastatic non-TNBC, 0.95; metastatic TNBC, 0.93).
CONCLUSION: We recommend combining GATA3, SOX10, PAX8 expression profiling to confirm breast as the site of origin in metastatic MBC.
Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  GATA3; PAX8; SOX10; breast cancer; triple-negative breast cancer.

Mesh:

Substances:

Year:  2022        PMID: 34972751      PMCID: PMC8765136          DOI: 10.21873/invivo.12727

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  26 in total

1.  Sox10--a marker for not only schwannian and melanocytic neoplasms but also myoepithelial cell tumors of soft tissue: a systematic analysis of 5134 tumors.

Authors:  Markku Miettinen; Peter A McCue; Maarit Sarlomo-Rikala; Wojciech Biernat; Piotr Czapiewski; Janusz Kopczynski; Lester D Thompson; Jerzy Lasota; Zengfeng Wang; John F Fetsch
Journal:  Am J Surg Pathol       Date:  2015-06       Impact factor: 6.394

Review 2.  Metastatic carcinoma of unknown primary: diagnostic approach using immunohistochemistry.

Authors:  James R Conner; Jason L Hornick
Journal:  Adv Anat Pathol       Date:  2015-05       Impact factor: 3.875

3.  Utility of Sox10 labeling in metastatic breast carcinomas.

Authors:  Emily R Nelson; Rajni Sharma; Pedram Argani; Ashley Cimino-Mathews
Journal:  Hum Pathol       Date:  2017-08-23       Impact factor: 3.466

4.  A combination of GATA3 and SOX10 is useful for the diagnosis of metastatic triple-negative breast cancer.

Authors:  Gary H Tozbikian; Debra L Zynger
Journal:  Hum Pathol       Date:  2018-11-20       Impact factor: 3.466

5.  Microphthalmia transcription factor in the immunohistochemical diagnosis of metastatic melanoma: comparison with four other melanoma markers.

Authors:  M Miettinen; M Fernandez; K Franssila; Z Gatalica; J Lasota; M Sarlomo-Rikala
Journal:  Am J Surg Pathol       Date:  2001-02       Impact factor: 6.394

6.  Intratumor Heterogeneity of Synchronous In Situ and Invasive Breast Carcinoma Revealed Using Multi-region Exome Sequencing.

Authors:  Hayeon Kim; Jeong-An Gim; Chung-Yeul Kim; Aeree Kim
Journal:  Anticancer Res       Date:  2021-08       Impact factor: 2.480

7.  WT1 immunoreactivity in breast carcinoma: selective expression in pure and mixed mucinous subtypes.

Authors:  Akosua B Domfeh; AnnaMarie L Carley; Joan M Striebel; Rouzan G Karabakhtsian; Anca V Florea; Kim McManus; Sushil Beriwal; Rohit Bhargava
Journal:  Mod Pathol       Date:  2008-05-09       Impact factor: 7.842

8.  Neural crest transcription factor Sox10 is preferentially expressed in triple-negative and metaplastic breast carcinomas.

Authors:  Ashley Cimino-Mathews; Andrea P Subhawong; Hillary Elwood; Hind Nassar Warzecha; Rajni Sharma; Ben Ho Park; Janis M Taube; Peter B Illei; Pedram Argani
Journal:  Hum Pathol       Date:  2012-12-20       Impact factor: 3.466

9.  Cytokeratin 7, GATA3, and SOX-10 is a Comprehensive Panel in Diagnosing Triple Negative Breast Cancer Brain Metastases.

Authors:  Eric Statz; Julie M Jorns
Journal:  Int J Surg Pathol       Date:  2021-02-05       Impact factor: 1.271

Review 10.  Novel uses of immunohistochemistry in breast pathology: interpretation and pitfalls.

Authors:  Ashley Cimino-Mathews
Journal:  Mod Pathol       Date:  2020-10-27       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.